Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Therma Bright ( (TSE:THRM) ).
Therma Bright has received a follow-on order for 200 additional Venowave VW5 units from its Texas-based distributor Gen-X Med, expanding their partnership after a successful initial rollout in the U.S. orthopedic market. The units will be deployed primarily for post-surgical knee recovery, underscoring rising clinical demand for mobile, at-home compression therapy solutions and positioning Venowave—currently the only Medicare-reimbursable mobile mechanical compression system in the U.S.—to benefit from broader adoption as the global compression therapy market grows, driven by aging demographics, more orthopedic procedures and increased focus on preventing circulatory disorders.
The most recent analyst rating on (TSE:THRM) stock is a Sell with a C$0.06 price target. To see the full list of analyst forecasts on Therma Bright stock, see the TSE:THRM Stock Forecast page.
Spark’s Take on TSE:THRM Stock
According to Spark, TipRanks’ AI Analyst, TSE:THRM is a Neutral.
The score is driven primarily by weak financial performance (tiny revenue base, persistent losses, negative equity, and ongoing cash burn). Technicals are mixed with only a modest short-term improvement versus a still-weak longer-term trend, while valuation is constrained by negative earnings and no provided dividend yield.
To see Spark’s full report on TSE:THRM stock, click here.
More about Therma Bright
Therma Bright Inc. is a Toronto-based developer and investment partner focused on advanced diagnostic and medical device technologies, with a portfolio spanning vascular health, respiratory diagnostics and topical treatments. The company, listed on the TSX Venture Exchange, OTCQB and Frankfurt Stock Exchange, markets products such as the Venowave VW5, a compact, portable compression device aimed at improving circulatory health and accelerating post-operative recovery, particularly in high-growth therapeutic areas like orthopedic surgery.
Average Trading Volume: 54,291
Technical Sentiment Signal: Sell
Current Market Cap: C$3.77M
For an in-depth examination of THRM stock, go to TipRanks’ Overview page.